Business Context and Reporting Period
Company: Universe Pharmaceuticals INC
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: February 2026
Date Filed: February 11, 2026
Principal Executive Offices: 265 Jingjiu Avenue, Jinggangshan Economic and Technological Development Zone, Ji'an, Jiangxi, China 343100
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of a corporate governance event rather than a financial results announcement.
Material Changes and Corporate Actions
- Dual-Class Share Structure: The company announced the effective date of a dual-class share structure via a press release included as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary on operations, risks, contingencies, or unusual items beyond the announcement of the share structure change.
Investor Verification Checklist
- Verify the specific terms and effective date of the dual-class share structure in the attached press release (Exhibit 99.1).
- Confirm the voting rights and economic rights associated with the new share classes.
- Review the company's Form 20-F for the most recent audited financial statements, as this 6-K contains no financial data.